Niagen Bioscience to Showcase Research at Sixth Annual Longevity Summit at Buck Institute

Niagen Bioscience to Support Sixth Annual Longevity Summit, Highlighting NAD+ Research and Healthy Aging Innovations

Niagen Bioscience, a global leader in nicotinamide adenine dinucleotide (NAD+) research with a focus on the science of healthy aging, announced that it will support the Sixth Annual Longevity Summit, scheduled to take place December 9–10, 2026, at the Buck Institute for Research on Aging in Novato, California. The event will bring together leading researchers, investors, government organizations and other stakeholders to explore scientific advancements and strategies for translating longevity research into potential medical treatments.

The 2026 Longevity Summit will be held under the theme “The Future of Medicine: Eliminating Diseases of Aging.” The meeting will focus on emerging developments in aging biology, therapeutic innovation and research approaches designed to address age-related diseases. Through scientific presentations and discussions, participants will examine opportunities to transform discoveries in longevity science into clinically meaningful interventions that could improve healthspan and quality of life.

As part of its participation, Niagen Bioscience will highlight its research initiatives involving NAD+ biology, nicotinamide riboside (NR) supplementation and the potential role of NAD+ in supporting healthy aging. Abhijit Kale, Ph.D., Senior Director of Global External Research at Niagen Bioscience, will deliver a presentation titled “Shaping the Future of NAD+ Research: From Niagen® Science to Healthy Aging.”

His presentation will examine how the company’s flagship patented NR ingredient, Niagen®, and its Niagen Research Program have contributed to expanding scientific understanding of NAD+ through collaborations with leading academic and research institutions worldwide.

The presentation will also address the company’s evolving research strategy, which aims to translate discoveries in NAD+ biology into meaningful insights concerning healthy aging, healthspan and clinically relevant health outcomes. Niagen Bioscience plans to emphasize the importance of strategically designed clinical research, biomarker-driven investigations and international scientific collaborations in advancing the understanding of NAD+ and its potential applications in preventive health and therapeutic development.

Niagen Research Program Expands Global NAD+ Scientific Evidence

Niagen Bioscience has established its research activities around NAD+, an essential coenzyme involved in numerous cellular processes, including energy metabolism, mitochondrial function, DNA repair and cellular signaling.

NAD+ is present in virtually all living cells and plays a fundamental role in maintaining normal cellular activity. It participates in metabolic reactions that convert nutrients into energy and supports enzymes involved in regulating cellular stress responses and maintaining genomic stability.

Scientific interest in NAD+ has increased as researchers investigate how changes in NAD+ metabolism may be associated with aging and age-related health conditions. NAD+ levels and related metabolic processes may change with age, potentially influencing several biological pathways involved in cellular function.

Through its Niagen Research Program, Niagen Bioscience has sought to build a comprehensive scientific foundation for understanding how nicotinamide riboside can influence NAD+ metabolism and what these changes may mean for human health.

The company reported that its research program has established more than 320 research agreements across over 30 countries. Its research portfolio includes more than 240 peer-reviewed publications, including over 50 peer-reviewed clinical studies involving Niagen. More than 92% of these clinical studies were conducted independently.

These research activities have involved collaborations with internationally recognized institutions, including Stanford University, Johns Hopkins University, Mayo Clinic, Harvard University, the Massachusetts Institute of Technology (MIT) and the National Institutes of Health (NIH).

The collaborations have contributed to a growing body of scientific literature examining NAD+ metabolism, NR supplementation and related biological mechanisms.

At the Longevity Summit, Dr. Kale will discuss how the research program is entering its next phase, with a stronger emphasis on translating fundamental NAD+ biology into clinically relevant findings.

Rather than focusing exclusively on changes in NAD+ levels, the company’s research strategy is intended to investigate how NAD+ augmentation may relate to broader measures of health and biological function.

Key areas of interest include healthspan, functional capacity, biomarkers of biological aging and outcomes that may help determine whether interventions targeting NAD+ metabolism can provide meaningful benefits as individuals grow older.

Healthspan refers to the number of years a person lives in good health, maintaining physical, cognitive and functional abilities. It has become an increasingly important focus of longevity research because extending lifespan alone does not necessarily ensure that individuals remain healthy and independent throughout their lives.

Niagen Bioscience’s research strategy aims to contribute to this evolving scientific field through carefully designed studies and collaborations with academic institutions.

Collaboration With Mass General Brigham Advances Healthy Aging Research

An important development in the company’s healthy-aging research strategy was the start-up agreement announced with Mass General Brigham (MGB) in September 2026.

The agreement establishes the groundwork for a proposed first-of-its-kind healthy-aging prevention clinical trial evaluating Niagen in apparently healthy adults aged 50 years and older.

The proposed study is expected to be a multi-year, randomized, placebo-controlled clinical investigation designed to examine whether sustained NAD+ augmentation through Niagen supplementation may influence important measures of health and aging.

The research initiative is being developed by Howard Sesso, ScD, MPH, an investigator at Mass General Brigham, Associate Director of the Division of Preventive Medicine at Brigham and Women’s Hospital, and Associate Professor of Medicine at Harvard Medical School, in collaboration with the Niagen Research Program.

The proposed clinical trial is intended to evaluate several dimensions of healthy aging rather than concentrating on a single biological marker.

Planned areas of assessment include major clinical outcomes, functional measures of intrinsic capacity, biomarkers of biological aging and other measures associated with healthy aging.

Intrinsic capacity refers to the combination of an individual’s physical and mental capabilities that support independent functioning and overall well-being. Evaluating these measures may help researchers better understand how biological changes associated with aging relate to an individual’s ability to maintain everyday activities and functional independence.

The study is expected to investigate whether long-term NAD+ augmentation can produce measurable changes in these areas.

By using a randomized, placebo-controlled design, the proposed research aims to generate more robust evidence regarding the potential effects of Niagen in an apparently healthy aging population.

The initiative represents an important development in the company’s efforts to expand NAD+ research beyond conventional supplementation studies and toward broader prevention-oriented clinical investigations.

However, the study’s final design details remain subject to the completion of definitive agreements.

At the Longevity Summit, Dr. Kale is expected to discuss how this research approach could be expanded through additional global collaborations and biomarker-driven clinical studies.

These investigations may incorporate different forms of Niagen, including oral food-grade formulations and pharmaceutical-grade intravenous and injectable preparations, depending on the specific research objectives and development requirements.

The company’s broader objective is to establish a stronger scientific understanding of how NAD+ biology may contribute to healthy aging and whether interventions targeting this pathway can influence clinically meaningful outcomes.

Research Strategy Extends Into Rare Genetic Diseases

In addition to its prevention-focused research activities, Niagen Bioscience is exploring the potential application of NAD+ biology in rare genetic diseases and age-related disorders.

The company’s research findings have helped inform investigations into conditions in which NAD+-dependent biological processes, including DNA repair and mitochondrial function, may be impaired.

These cellular processes are essential for maintaining normal tissue function and responding to biological stress.

DNA repair mechanisms help protect genetic material from damage, while mitochondria play a central role in cellular energy production and metabolic regulation. Disruptions in these processes can contribute to cellular dysfunction and may be particularly relevant in certain inherited disorders associated with accelerated aging.

To advance its pharmaceutical development strategy, Niagen Bioscience recently announced the establishment of NAD Pharmaceuticals Corp., a wholly owned subsidiary focused on developing potential treatments for rare genetic diseases and age-related disorders.

The subsidiary represents an expansion of the company’s activities beyond its established NAD+ ingredient and research business into investigational pharmaceutical development.

The strategy is intended to apply the scientific knowledge generated through the Niagen Research Program to the development of therapeutic candidates targeting specific biological conditions.

One of the key developments emerging from this initiative is NB4168, the first investigational therapeutic candidate identified by the subsidiary.

NB4168 Advances as an Investigational Candidate for Ataxia-Telangiectasia

NB4168 is an oral small-molecule investigational candidate designed to deliver significantly increased doses of nicotinamide riboside into the bloodstream.

The candidate is initially being developed for Ataxia-Telangiectasia (A-T), a rare genetic disorder caused by mutations in the ATM gene.

Ataxia-Telangiectasia is a complex inherited condition that affects multiple systems in the body. The disease can involve neurological deterioration, impaired coordination, immune system abnormalities and increased susceptibility to certain cancers.

The ATM gene plays an important role in detecting and responding to DNA damage. The protein produced by this gene is involved in coordinating cellular responses to DNA double-strand breaks and maintaining genomic stability.

When mutations impair ATM function, affected cells may experience difficulties repairing DNA damage and managing cellular stress. These abnormalities contribute to the diverse clinical features associated with A-T.

The condition also has characteristics associated with accelerated aging, making it an area of interest for researchers investigating the relationship between cellular maintenance mechanisms, NAD+ metabolism and age-related biological processes.

Niagen Bioscience is developing NB4168 based on the scientific rationale that increasing NR availability may help support NAD+-dependent cellular pathways.

NR is a precursor used by cells to produce NAD+. By providing the body with NR, researchers aim to influence NAD+ availability and investigate its potential effects on cellular metabolism and related biological functions.

NB4168 has been designed to deliver substantially increased NR doses to the bloodstream through an oral small-molecule approach.

Its initial development focus on A-T reflects the company’s interest in exploring NAD+ biology in diseases where cellular processes such as DNA repair and mitochondrial function may be compromised.

The development of NB4168 represents an important step in Niagen Bioscience’s transition toward pharmaceutical research and development.

The candidate remains investigational and has not been approved for any use. Further research and clinical evaluation will be required to establish its safety, tolerability and potential therapeutic benefits in patients with Ataxia-Telangiectasia.

The company intends to use its growing understanding of NAD+ biology to identify additional opportunities in rare genetic diseases and age-related conditions.

Longevity Summit to Highlight Translation of Aging Research Into Medicine

The Sixth Annual Longevity Summit will provide a platform for discussions surrounding the scientific and clinical opportunities emerging from longevity research.

Scheduled for December 9–10, 2026, at the Buck Institute for Research on Aging in Novato, California, the event will bring together researchers, investors and government organizations interested in advancing the science of aging and developing interventions for age-related diseases.

The 2026 theme, “The Future of Medicine: Eliminating Diseases of Aging,” reflects the growing emphasis on translating discoveries in aging biology into potential therapeutic strategies.

Research into aging has expanded significantly, with scientists investigating cellular senescence, mitochondrial dysfunction, inflammation, metabolic changes, DNA damage and other biological mechanisms that may contribute to age-related disease.

The summit is expected to provide opportunities for stakeholders to discuss how discoveries in these areas can be translated into clinical development programs and potential medical interventions.

Niagen Bioscience’s participation will focus on the role of NAD+ biology within this broader research landscape.

Through Dr. Kale’s presentation, the company plans to highlight its scientific collaborations, published research, clinical development initiatives and emerging pharmaceutical programs.

The presentation will also emphasize the importance of moving beyond preliminary biological findings toward clinical evidence that can establish whether interventions targeting NAD+ metabolism have meaningful effects on healthspan.

For Niagen Bioscience, the event represents an opportunity to communicate the progress of its research program and its evolving strategy across healthy aging and rare disease development.

Niagen Bioscience Expands Its Research and Development Vision

Niagen Bioscience’s support for the 2026 Longevity Summit reflects its continued commitment to NAD+ science and the development of research initiatives focused on healthy aging.

The company’s strategy encompasses several interconnected areas, including scientific collaborations, clinical investigations, biomarker research and pharmaceutical development.

Its Niagen Research Program has established a substantial international research network, with more than 320 research agreements and over 240 peer-reviewed publications. These activities provide a foundation for further investigations into the biological functions of NAD+ and the potential applications of NR.

The proposed Mass General Brigham prevention trial represents an important step toward evaluating the relationship between sustained NAD+ augmentation and broader measures of healthy aging in adults aged 50 and older.

At the same time, the establishment of NAD Pharmaceuticals Corp. and the advancement of NB4168 demonstrate the company’s interest in applying NAD+ research to rare genetic diseases with significant unmet medical needs.

Through its participation in the Sixth Annual Longevity Summit, Niagen Bioscience intends to highlight how its research initiatives are evolving from foundational NAD+ science toward clinical studies and investigational therapeutic development.

Although the potential benefits of NAD+ augmentation and the therapeutic applications of NB4168 remain subjects of ongoing research, the company’s expanding scientific and development activities reflect the increasing interest in understanding the biological mechanisms of aging and identifying new approaches to improve human health.

The December summit will provide an opportunity for Niagen Bioscience to share its research progress and engage with the broader longevity science community as it continues pursuing its goal of translating NAD+ research into clinically relevant insights and potential treatments.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically tested product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com).

Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter